Loading
Loading
Research Overview
Recombinant human growth hormone; activates GHR/JAK2/STAT5 signalling cascade to promote IGF-1 production, protein synthesis, lipolysis, and cell proliferation across multiple tissue types.
Recombinant human growth hormone is a single-chain polypeptide produced by somatotroph cells of the anterior pituitary gland and widely used in laboratory research as a reference standard and pharmacological tool for studying GH biology. Preclinical research has employed rhGH to characterise growth hormone receptor signalling through the JAK2-STAT5 pathway, downstream IGF-1 production in liver and peripheral tissues, and the tissue-specific anabolic and metabolic consequences of GH receptor activation.
In preclinical metabolic research, growth hormone has been studied for its complex role in regulating lipolysis, protein synthesis, and carbohydrate metabolism in animal models. Laboratory investigations have characterised how GH promotes fatty acid mobilisation from adipose tissue while stimulating protein anabolism in skeletal muscle, and how these effects interact with insulin signalling in models of metabolic regulation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, human growth hormone (hgh / somatropin) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Human Growth Hormone (HGH / Somatropin) research is most relevant to protocols examining:
GH deficiency treatment research and replacement protocols
Anti-ageing body composition and metabolism studies
IGF-1 axis research examining downstream anabolic signalling
Wound healing and recovery enhancement investigations
Paediatric growth disorder research models
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~3–4 hours sub-q). Review data, confirm baseline recovery before any repeat protocol.
Recombinant human growth hormone; activates GHR/JAK2/STAT5 signalling cascade to promote IGF-1 production, protein synthesis, lipolysis, and cell proliferation across multiple tissue types.
| Parameter | Value |
|---|---|
| Dose range | 1–4 IU/day (research) |
| Alt. dose 2 | 0.5–1 IU/day (anti-ageing protocols) |
| Schedule | Daily or 5 days on / 2 days off |
| Route | Subcutaneous, Intramuscular |
| Half-life | ~3–4 hours sub-q |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.